Partner
- christina.takke@forbion.com
- Download vCard 
Christina Takke was appointed Partner with Forbion Capital Partners in 2010 and has over 10 years investment expertise in the Life Science sector. She joined the group (previously ABN AMRO Capital Life Sciences) as analyst in 2000.
At Forbion Capital Partners, Christina is responsible for scouting and the analysis of new investment opportunities as well as the general deal execution. Christina has been instrumental in the financing of several Forbion portfolio companies by coordinating due diligence for the international syndicates for which the group acted as lead investor. Recently she led the Series A investment in arGEN-X.
Further Christina serves on the supervisory boards of arGEN-X BV (The Netherlands), Pieris AG (Germany), Bioceros BV (The Netherlands) and was closely involved with GlycArt (Switzerland) as an observer prior to its sale to Roche in 2005.
Before joining ABM AMRO in 2000, she worked with Bio-Gen-Tec-NRW, a regional development organization for the biotechnology industry, which was based in Cologne, Germany. Here she evaluated business proposals and assisted companies in the fundraising process.
Christina began her scientific career with a master’s degree in biology from the Technical University of Darmstadt. She subsequently joined the group of Prof Dr, Campos-Ortega at the Institute of Development Biology of the University of Cologne, where she studied the Delta-Notch signaling pathway and its role during zebra fish neurogenesis and early somite development.
